Microban and Cleanwaste Medical Unveil the new Sani-Bag+ with Built-in Antimicrobial Technology

Microban International is pleased to unveil a new partnership with Cleanwaste Medical to develop the Sani-Bag+ with built-in Microban® antimicrobial product protection. This industry-leading antimicrobial technology helps to protect the commode and bedpan liners from the growth of odor-causing bacteria, and complements Cleanwaste Medical’s proprietary formulation of deodorizing technology and NASA-developed absorbent gel polymer to create waste management solutions that are cleaner and more discreet.

The Sani-Bag+ has been meticulously designed and engineered with Microban technology to address the pressing need for clean and user-friendly disposable commode and bedpan liners in healthcare settings. The addition of innovative Microban® antimicrobial technology sets a new industry standard, further elevating the functionality of these bags to provide a fresher, more comfortable and more dignified experience for the user.

Michael Ruby, President at Microban International, commented:

“Microban is extremely proud of its partnership with Cleanwaste Medical, which brings together the expertise of both companies to deliver a practical and reliable solution for clean waste management. With over 30 years of industry leading experience, Microban’s antimicrobial technologies enhance the cleanliness of these liners by helping to prevent the growth of bacteria, ensuring fresher, cleaner and more convenient solutions for consumers and professionals.”

Sam Alhmad, National Sales Manager at Cleanwaste Medical added:

“We are very excited to partner with a trusted company of Microban’s caliber, and develop a line of antimicrobial Sani-Bag+ products that truly fulfill an unmet need, setting us apart from our competitors. These bags have been carefully designed to deliver a solution with enhanced antimicrobial performance that revolutionizes the user experience and is easily disposed of to prevent contact with waste. Microban® antimicrobial product protection is the perfect addition to these products, marrying up with our proprietary odor-neutralizing and waste absorbance technologies to make these liners the go-to choice for healthcare settings.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version